School of Pharmacy

Staff Profile

Professor Moein Moghimi

Professor of Pharmaceutics and Nanomedicine


Since August 2017, Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine (School of Pharmacy) and Research Professor (Institute of Cellular Medicine) at Newcastle University (UK). He is also an Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA). His earlier appointments have included Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health, Durham University, UK (2016-2017); Full Affiliate Member/Professor at the Methodist Research Institute, Houston Methodist Hospital Systems, Houston, Texas, USA (2013-2017); Visiting Professor at Università Degli Studi Di Padova, Padova, Italy (2015), where he designed and delivered the first integrated Nanomedicine-Business course in Europe with Dr. Farhangrazi (Denver University and Biotrends International);  Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical Nanotechology at the NanoScience Centrer, and Founder/Director of the multi-million Dollar Center for Pharmaceutical Nanotechnology and Nanotoxiocology at the University of Copenhagen, Denmark (2008-2015); Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University, China (2008-2010); Senior Lecturer in Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton, UK (1998-2008); and University Research Fellow in Advanced Drug Delivery Systems at the Department of Pharmaceutical Sciences, University of Nottingham, UK. Moein studied Biochemistry at the University of Manchester (1982-1985) and obtained his PhD in Biochemistry from Charing Cross and Westminster Medical School (Imperial College London) (July 1988). 

Professor Moghimi further functions as Deputy Editor for Molecular Therapy (Cell Press) and Associate Editor for Journal of Biomedical Nanotechnology (American Scientific Publishers) and Precision Nanomedicine (Andover House, Massachusetts). Between 2010 and 2016, he served as Associate Editor for Nanomedicine (Elsevier). Professor Moghimi also features on editorial board of several peer-reviewed international journals including Advanced Drug Delivery Reviews (Elsevier), Drug Delivery (Taylor Francis), Journal of Controlled Release (Elsevier), Nanomedicine (Lond.) (Future Medicine), Nanomaterials (Basel) and Scientific Reports (Springer Nature).

AREAS OF EXPERTISE: Nanomedicine; Drug delivery; Nanotoxicology; Formulation science



ORCID i.d.:

SCOPUS i.d.: 7003709762

A Selection of our peer-reviewed publications:

  1. Farhangrazi, Z.S., Sancini, G., Hunter, A.C. and Moghimi, S. M. (2020) Airborne particulate matter and SARS-CoV-2 partnership: virus hitchhiking, stabilization and immune cell targeting - A hypothesis. Frontiers in Immunology (in press).
  2. Pannuzzo, M., Esposito, S., Wu, L-P., Key, J., Aryal, S., Celia, C., di Marzio, L., Moghimi, S.M. and Decuzzi, P. (2020) Overcoming nanoparticle-mediated complement activation by surface PEG-pairing.  Nano Letters 20: 4312–4321.
  3. Helvig, S.Y., Woythe, L., Pham, S., Bor, G., Andersen, H., Moghimi, S.M. and Yaghmur, A. (2020) A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing tunable complement activation properties. Journal of Colloid and Interface Science (in press).
  4. Farhangrazi, Z.S. and Moghimi, S. M. (2020) Elevated circulating endothelin-1 as a potential biomarker for high-risk COVID-19 severity. Precision Nanomedicine 3622–628.
  5. Moghimi, S.M., Simberg, D., Papini, E. and Farhangrazi, Z.S. (2020) Complement activation by drug carriers and particulate pharmaceuticals: principles, challenges and opportunities. Advanced Drug Delivery Reviews (in press).
  6. Decuzzi, P., Di Mascolo, D., Palange, A.L., Manghnani, P.N., Moghimi, S.M., Farhangrazi, Z.S., Howard, K.A., Rosenblum, D., Liang, T., Chen, Z., Wang, Z., Zhu, J-J., Gu, Z., Korin, N., Letourneur, D., Chauvierre, C., van der Meel, R., Kiessling, F. and Lammers, T. (2020) Roadmap on nanomedicine. Nanotechnology (in press).
  7. Moghimi, S.M. and Farhangrazi, Z.S. (2020) A rally for brain targeting: the advent of a new era. Therapeutic Delivery 11465–470. 
  8. Moghimi, S.M., Simberg, D. and Anchordoquy, T.J. (2020) Tuning the engines of nanomedicine. Molecular Therapy 28693–694.
  9. Helvig, S. Y., Andersen, H., Antopolsky, M., Airaksinen, A., Urtti, A., Yaghmur, A. and Moghimi, S.M. (2020) Hexosome engineering for targeting of regional lymph nodes. Materialia (Oxf.) 11: 100705.
  10. Wu, L-P., Ahmadvand, D., Su, J., Hall, A., Tan, X., Farhangrazi, Z.S. and Moghimi, S.M. (2019) Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. Nature Communications 10: 4635. doi: 10.1038/s41467-019-12554-2                                                                                                                                           
  11. Vu, V.P., Gifford, G.B., Chen, F., Benasutti, H., Wang, G., Groman, E.V., Scheinman, R., Saba, L., Moghimi, S.M. and Simberg, D. (2019) Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles. Nature Nanotechnology 14: 260–268.
  12. Hall, A., Maynard, S., Wu, L-P., Merchut-Maya, J. M., Strauss, R., Jäättelä, M., Moghimi, S. M. and Bartek, J. (2019) Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. Journal of Controlled Release 309: 158–172.
  13. Gifford, G., Vu, V.P., Banda, N.K., Holers, V.M., Wang, G., Groman, E., Backos, D., Scheinman, R., Moghimi, S.M. and Simberg, D. (2019) Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. Journal of Controlled Release 302: 181–189.
  14. Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., Dobrovolskaia, M. A., Kozlov, S. V., Prina-Mello, A., Schmid, R., Wick, P., Caputo, F., Boisseau, P., Crist, R. M., McNeil, S. E., Fadeel, B., Tran, L., Hansen, S. F., Hartmann, N. B., Clausen, L. P. W., Skjolding, L. M., Baun, A., Ågerstrand, M., Gu, Z., Lamprou, D. A., Hoskins, C., Huang, L., Song, W., Cao, H., Liu, X., Jandt, K. D., Jiang, W., Kim, B. Y. S., Wheeler, K. E., Chetwynd, A. J., Lynch, I., Moghimi, S. M., Nel, A., Xia, T., Weiss, P. S., Sarmento, B., das Neves, J., Santos, H. A., Santos, L., Mitragotri, S., Little, S., Peer, D., Amiji, M. M., Alonso, M. J., Petri-Fink, A., Balog, S., Lee, A., Drasler, B., Rothen-Rutishauser, B., Wilhelm, S., Acar, H., Harrison, R. G., Mao, C., Mukherjee, P., Ramesh, R., McNally, L. R., Busatto, S., Wolfram, J., Bergese, P., Ferrari, M., Fang, R. H., Zhang, L., Zheng, J., Peng, C., Du, B., Yu, M., Charron, D. M., Zheng, G. and Pastore, C. (2019) On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology 14: 629–635.
  15. Moghimi, S.M., Simberg, D., Skotland, T., Yaghmur, A. and Hunter, A.C. (2019) The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. Journal of Pharmacology and Experimental Therapeutics 370: 581–592.
  16. Moghimi, S.M. and Peer, D. (2019) Reprogramming the lymphocytes axis for advanced immunotherapy. Advanced Drug Delivery Reviews 141: 1–2. 
  17. Rahbarizadeh, F., Ahmadvand, D. and Moghimi, S.M. (2019) CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews 141: 41–46.
  18. Tavano, R., Gabrielli, L., Lubian, E., Fedeli, C., Visentin, S., De Laureto, P. P., Arrigoni, G., Geffner-smith, A., Chen, F., Simberg, D., Morgese, G., Benetti, E.M., Wu, L., Moghimi, S.M., Mancin, F. and Papini, E. (2018) C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly(2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano 12: 5834–5847.
  19. Moghimi, S.M. (2018) Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discovery Today 23: 1034–1042.
  20. Moghimi, S.M. and Howard. K.A. (2018) Targeting biological barriers: turning a wall into a therapeutic springboard. Molecular Therapy 26: 933–944.
  21. Griffin, J.I., Wang, G., Smith, W.J., Vu, V.P., Scheinman, R., Stitch, D., Moldovan, R., Moghimi, S. M. and Simberg, D. (2017) Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy. ACS Nano 11: 11584–11593.
  22. Wibro, P.P., Anselmo, A. C., Nilsson, P., Sarode, A., Gupta, V., Urbanics, R., Szebeni, J., Hunter, A.C., Mitragotri, S., Mollnes, T.E.  and Moghimi, S.M. (2017) By-passing injection reactions to nanoparticles through shape modification and attachment to erythrocyte. Nature Nanotechnology 12: 589–594.
  23. Ordóñez-Gutiérrez, L., Posado-Fernández, A., Ahmadvand, D., Lettiero, B., Wu, L. P., Antón, M., Flores, O., Moghimi, S. M. and Wandosell, F. (2017) ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer’s disease is restricted to aged animals. Biomaterials 112: 141–152.
  24. Chen, F., Wang, G., Griffin, J., Brenneman, B., Banda, N. K., Holers, V.M. , Backos, D. S., Wu, L-P., Moghimi, S.M. and Simberg, D. (2017) Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nature Nanotechnology 12: 387–393.
  25. Anchordoquy, T., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Debrovolskaia, M., Farhangrazi, Z.S., Farrell,  D., Gabizon, A., Ghandehari, H.R., Godin, B.,  La-Beck, N.H., Ljubimova, J., Moghimi, S.M., Pagliano, L., Park, J-H., Peer, D., Ruoslahti, E., Serkova, N.J. and D. Simberg (2017) Mechanisms and barriers in anti-cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 11: 12–18.
  26. Moghimi, S.M. and Simberg, D. (2017) Complement activation turnover on surfaces of nanoparticles. Nano Today 15: 8–10.
  27. Wibroe, P. P., Petersen, S. V., Bovet, N., Laursen, B. W. and Moghimi, S. M. (2016) Soluble and immobilized graphene oxide activates the complement differently dependent on surface oxidation state. Biomaterials 78: 20–126.
  28. Inturi, S., Wang, G., Chen, F., Banda, N. K., Holers, V.M., Moghimi, S.M. and Simberg, D. (2015) Modulatory role of surface coating of superparamagnetic iron oxide nanoworms on complement opsonisation and leukocytes uptake. ACS Nano 9: 10758–10768.
  29. Whitehead, B., Wu, L-P., Hvam, M. L., Aslan, H., Dong, M., Dyrskjøt, L., Ostenfeld, M. S., Moghimi, S. M. and Howard, K. A. (2015). Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. Journal of Extracellular Vesicles 4: 29685 –
  30. Rahimi Jamnani, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Rahbrizadeh, F., Parhamifar, L. and Moghimi, S. M. (2014) T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumour-directed oligoclonal T cell therapy. Biochimica et Biophysica. Acta – General Subjects 1840: 378–386.
  31. Andersen, A. J., Robinson, J. T., Dai, H., Hunter, A. C., Andresen, T. L. and Moghimi, S. M. (2013) Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7: 1108–1119.
  32. Benjaminsen, R.V., Mattebjerg, M.A., Henriksen, J. R., Moghimi, S.M. and Andresen, T.L. (2013) The possible ‘proton-sponge’ effect of polyethylenimine does not include change in lysosomal pH. Molecular Therapy 21: 147–157.
  33. Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kona, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S.M., Tvaroska, I., Couvreur, P. and Andrieux, K. (2012) PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: towards engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano 6: 5897–5908.
  34. Moghimi, S.M., Hunter, A.C. and Andresen, T.L. (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annual Review of Pharmacology and Toxicology 52: 481–503.
  35. Moghimi, S.M., Peer, D. and Langer R. (2011) Re-shaping the future of nanopharmaceuticals: ad iduicium. ACS Nano 5: 8454–8458.
  36. Hamad, I., Al-Hanbali, O., Hunter, A.C., Rutt, K.J., Andresen, T.L. and Moghimi, S. M. (2010) Distinct polymer architecture mediates switching of complement activation pathways at nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4: 6629–6638.
  37. Moghimi, S.M. and Hunter, A. C. (2010) Complement monitoring of carbon nanotubes. Nature Nanotechnology 5: 382–382.
  38. Hamad, I., Hunter, A. C., Szebeni, J. and Moghimi, S. M. (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology 46: 225–232.
  39. Mukhopadhyay, R., Al-Hanbali, O., Pillai, S., Hemmersam, A.G., Meyer, R.L., Hunter, A.C., Rutt, K.J., Besenbacher, F., Moghimi, S.M. and Kingshott, P. (2007) Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. Journal of the American Chemical Society 129: 13390–13391. 
  40. Moghimi, S.M., Hamad, I., Andresen, T.L., Jorgensen, K. and Szebeni, J. (2006) Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB Journal 20: 2591–2593. Full-Length Article: 
  41. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.
  42. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2005) Nanomedicine: current status and future prospects. FASEB Journal 19: 311–330.
  43. Moghimi, S.M., Symonds, P., Murray, J.C., Hunter, A.C., Debska, G. and Szewczyk, A. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. Molecular Therapy 11: 990–995.
  44. Moghimi, S.M., Hunter, A.C., Murray, J.C. and Szewczyk, A. (2004) Cellular distribution of nonionic micelles. Science 303: 626–627. 
  45. Moghimi, S.M. and Szebeni, J. (2003) Stealth liposomes and nanoparticles: critical issues on protein-binding properties, activation of proteolytic blood cascades and intracellular fate. Progress in Lipid Research 42: 463–478.
  46. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2001) Long circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 53: 283–318.
  47. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.
  48. Moghimi, S. M. and Murray, J. C. (1996) Poloxamer-188 re-visited: a potentially valuable immune modulator? Journal of the National Cancer Institute 88: 766–768.
  49. Moghimi, S. M., Hawley, A. E., Christy, N. M., Gray, T., Illum, L. and Davis, S. S. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of lymph nodes. FEBS Letters 344: 25–30. 
  50. Porter, C. J. H., Moghimi, S. M., Illum, L., Davis, S. S. (1992) The polyoxyethylene/ polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Letters 68: 121–126.


Prof. Moghimi has made groundbreaking contributions to the field of advanced drug delivery, nanoparticle engineering, and nanopharmaceutical performance and safety. The work in Prof. Moghimi’s laboratory has employed an interdisciplinary state-of-the-art approach to study disease mechanisms with the aim of identifying realistic opportunities offered by understanding pathophysiolocal processes to the design and engineering of efficient and safe nanopharmaceuticals. Professor Moghimi’s research has advanced fundamental understanding of biological barriers, and particularly the role of innate immune system in relation to nanoparticle performance and safety. Throughout, his work has led to the development of new materials and approaches for treatment of various conditions to include cancer, cardiovascular diseases, immune disorders, and disease of the central nervous system.

Prof. Moghimi has received continuous and extensive funding support from numerous bodies (securing over 25 million Euros in competitive research from National and European Commission FP-7 Programmes as principal investigator and co-investigator), and created a global network of more than 40 renowned scientists at the forefront of experimental and clinical medicine as well as bioengineering.

The latest research activities in Prof. Moghimi’s laboratory are expected to push the boundary of the nanotherapies to a personalized level. Thus, the enabling solutions from Prof. Moghimi’s laboratory is being directed for better management and more effective treatment of diseases and chronic conditions associated with the growing aging population including cancer, neurological disorders (e.g., Alzheimer’s disease and Parkinson’s disease), cardiovascular diseases (e.g., atherosclerosis), arthritis, and allergy. The focus is not only directed on detailed mapping of nanopharmaceutical “structure-activity” relationships at single cell and molecular levels, but also on long-term concomitant extensive computational network knowledge of genomics and epigenomics of inter-individual variations to nanoformulation performance, and adverse drug and nanomaterial responses.